Investors

Shareholder Tools

 

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Recent Press Releases

Sep 22, 2014
Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B(TM)

Aug 7, 2014
Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug Candidates

View all releases »

E-Delivery of Stockholder Communications

Beneficial stockholders

Registered stockholders

Corporate Presentation

Annual Report and Proxy
2014 Proxy Statement
2013 Form 10-K